Tuesday, 17 November 2026NewsWorldBusinessTech
Latest

AriBio Pill Slows Alzheimer’s Decline in Monotherapy Group, Trial Finds

An oral Alzheimer’s treatment candidate developed by South Korean biotech firm AriBio slowed clinical decline by 31 percent in a prespecified monotherapy group during a global Phase 3 trial, though it failed to achieve statistical significance in the overall patient population.

AriBio announced the topline results from the POLARIS-AD trial on November 16, 2026, at the Clinical Trials on Alzheimer’s Disease conference in Boston. The global study enrolled 1,535 patients with early Alzheimer’s disease across approximately 230 clinical sites in 13 countries, including the United States.

Participants in the trial took either a 30-milligram pill of AR1001 or a placebo once daily for 52 weeks. The trial design established two prespecified primary analysis populations in consultation with regulators including the U.S. Food and Drug Administration and the European Medicines Agency.

Investigators divided the 0.05 overall significance threshold into 0.03 for the monotherapy cohort and 0.02 for the full cohort, designating the primary goal as successfully met if either of these two populations crossed the required significance bar.

Trial Results in the Monotherapy Group

The primary endpoint measured changes from baseline on the Clinical Dementia Rating-Sum of Boxes at week 52. In the 604-patient monotherapy group—participants who were not receiving acetylcholinesterase inhibitors or memantine at baseline—the AR1001 group showed a statistically significant treatment difference of -0.44 points versus placebo, representing a 31 percent slowing of clinical decline.

Researchers assessed deterioration using an 18-point scale covering memory, judgment, and everyday abilities. Throughout the 12-month study period, subjects receiving AR1001 within the smaller cohort experienced 0.44 points less decline relative to those given the inactive placebo, a difference that investigators equated to pushing back the progression of dementia symptoms by approximately 3.5 months.

AriBio's Oral Alzheimer's Drug Delays Decline 31% in Monotherapy Group
Photo: BigGo Finance

“The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer’s medications,” said Dr Scales.

However, when researchers analyzed all 1,535 patients together, including those taking other dementia medicines, the treatment difference was -0.11 points versus placebo, which did not reach statistical significance.

“POLARIS-AD met its primary efficacy objective in the pre-specified monotherapy group,” said Professor Sharon Sha, chief of the Memory Disorders Division at Stanford University and global principal investigator of the trial. She added that secondary endpoints showed trends favoring AR1001 and that cerebrospinal fluid analysis confirmed the drug acts on its target.

AR1001 Shows Improved Cognitive Measures and Biomarker Changes

Secondary cognitive and functional measures numerically favored AR1001 across both populations. In the monotherapy group, Mini-Mental State Examination scores were 0.7 points higher than the placebo group.

On the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13, the monotherapy group scored -1.16 points lower than placebo, a result that did not reach statistical significance. Cerebrospinal fluid analysis showed an increase in cyclic guanosine monophosphate, and a decrease in phosphorylated tau, with CSF p-tau217 results showing treatment differences versus placebo of -5.34 pg/mL in the monotherapy group.

From a safety standpoint, serious adverse events were documented in 10.0% of participants taking AR1001 and 9.8% of those in the placebo cohort.

AriBio Pill Slows Alzheimer's Decline in Monotherapy Group, Trial Finds
Photo: Carroll County Mirror-Democrat

Adverse events prompted therapy discontinuation among 5.2% of AR1001 subjects compared to 1.7% in the placebo arm, with dizziness, falls, and diarrhea highlighted among the most frequent negative reactions.

AriBio developed AR1001, also called mirodenafil. The company in-licensed the rights to develop AR1001 from SK Chemicals.

“The 31 percent clinical deterioration delay identified at the time of one year in the monotherapy group supports our hypothesis,” said Jaejun Jeong, CEO of AriBio. “Based on this global clinical result, we want to quickly enter the US Food and Drug Administration approval application.”

FDA Approves First Drug That Slows Cognitive Decline In Alzheimer's Patients — KPIX | CBS NEWS BAY AREA